PubMed:11106653 / 1476-1672 JSONTXT

{"project":"GlyCosmos6-Glycan-Motif-Image","denotations":[{"id":"T7","span":{"begin":72,"end":83},"obj":"Glycan_Motif"}],"attributes":[{"id":"A7","pred":"image","subj":"T7","obj":"https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G43702JT"}],"text":"Therefore, the development of therapeutics based on the model of A beta-chondroitin sulfate binding may lead to effective inhibitors of the GAG-induced amyloid formation that is observed in vitro."}

{"project":"Glycosmos6-GlycoEpitope","denotations":[{"id":"T5","span":{"begin":72,"end":83},"obj":"http://www.glycoepitope.jp/epitopes/EP0081"}],"text":"Therefore, the development of therapeutics based on the model of A beta-chondroitin sulfate binding may lead to effective inhibitors of the GAG-induced amyloid formation that is observed in vitro."}

{"project":"sentences","denotations":[{"id":"T9","span":{"begin":0,"end":196},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Therefore, the development of therapeutics based on the model of A beta-chondroitin sulfate binding may lead to effective inhibitors of the GAG-induced amyloid formation that is observed in vitro."}

{"project":"GlyCosmos6-Glycan-Motif-Structure","denotations":[{"id":"T7","span":{"begin":72,"end":83},"obj":"https://glytoucan.org/Structures/Glycans/G43702JT"}],"text":"Therefore, the development of therapeutics based on the model of A beta-chondroitin sulfate binding may lead to effective inhibitors of the GAG-induced amyloid formation that is observed in vitro."}

{"project":"mondo_disease","denotations":[{"id":"T5","span":{"begin":152,"end":159},"obj":"Disease"}],"attributes":[{"id":"A5","pred":"mondo_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/MONDO_0019065"}],"text":"Therefore, the development of therapeutics based on the model of A beta-chondroitin sulfate binding may lead to effective inhibitors of the GAG-induced amyloid formation that is observed in vitro."}

{"project":"Glycan-GlyCosmos","denotations":[{"id":"T13","span":{"begin":72,"end":83},"obj":"Glycan"}],"attributes":[{"id":"A13","pred":"glycosmos_id","subj":"T13","obj":"https://glycosmos.org/glycans/show/G43702JT"},{"id":"A26","pred":"image","subj":"T13","obj":"https://api.glycosmos.org/wurcs2image/latest/png/binary/G43702JT"}],"text":"Therefore, the development of therapeutics based on the model of A beta-chondroitin sulfate binding may lead to effective inhibitors of the GAG-induced amyloid formation that is observed in vitro."}

{"project":"GlyCosmos-GlycoEpitope","denotations":[{"id":"T5","span":{"begin":72,"end":83},"obj":"http://purl.jp/bio/12/glyco/glycan#Glycan_epitope"}],"attributes":[{"id":"A5","pred":"glycoepitope_id","subj":"T5","obj":"http://www.glycoepitope.jp/epitopes/EP0081"}],"text":"Therefore, the development of therapeutics based on the model of A beta-chondroitin sulfate binding may lead to effective inhibitors of the GAG-induced amyloid formation that is observed in vitro."}

{"project":"GlyCosmos15-MONDO","denotations":[{"id":"T5","span":{"begin":152,"end":159},"obj":"Disease"}],"attributes":[{"id":"A5","pred":"mondo_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/MONDO_0019065"}],"text":"Therefore, the development of therapeutics based on the model of A beta-chondroitin sulfate binding may lead to effective inhibitors of the GAG-induced amyloid formation that is observed in vitro."}

{"project":"sentences","denotations":[{"id":"T9","span":{"begin":0,"end":196},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Therefore, the development of therapeutics based on the model of A beta-chondroitin sulfate binding may lead to effective inhibitors of the GAG-induced amyloid formation that is observed in vitro."}

{"project":"GlyCosmos15-Sentences","blocks":[{"id":"T9","span":{"begin":0,"end":196},"obj":"Sentence"}],"text":"Therefore, the development of therapeutics based on the model of A beta-chondroitin sulfate binding may lead to effective inhibitors of the GAG-induced amyloid formation that is observed in vitro."}

{"project":"GlyCosmos15-Glycan","denotations":[{"id":"T13","span":{"begin":72,"end":83},"obj":"Glycan"}],"attributes":[{"id":"A13","pred":"glycosmos_id","subj":"T13","obj":"https://glycosmos.org/glycans/show/G43702JT"},{"id":"A26","pred":"image","subj":"T13","obj":"https://api.glycosmos.org/wurcs2image/latest/png/binary/G43702JT"}],"text":"Therefore, the development of therapeutics based on the model of A beta-chondroitin sulfate binding may lead to effective inhibitors of the GAG-induced amyloid formation that is observed in vitro."}

{"project":"GlyCosmos15-GlycoEpitope","denotations":[{"id":"T5","span":{"begin":72,"end":83},"obj":"http://purl.jp/bio/12/glyco/glycan#Glycan_epitope"}],"attributes":[{"id":"A5","pred":"glycoepitope_id","subj":"T5","obj":"http://www.glycoepitope.jp/epitopes/EP0081"}],"text":"Therefore, the development of therapeutics based on the model of A beta-chondroitin sulfate binding may lead to effective inhibitors of the GAG-induced amyloid formation that is observed in vitro."}